High-Dose-Rate Brachytherapy for Non–Small-Cell Lung Carcinoma: A Retrospective Study of 226 Patients

Guilcher, Maud Aumont–le; Prevost, B.; Sunyach, Marie Pierre; Peiffert, D.; Maingon, P.; Thomas, Laurence; Williaume, D.; Bègue, M.; Lerouge, D.; Campion, Loı̈c; Mahé, M.‐A.

doi:10.1016/j.ijrobp.2009.12.041

Cited by 48 publications

(21 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After reviewing the data, we found out that pneumothorax possibly resulted from tumor location, pulmonary function, biopsy needle diameter, rib blockage, and breathing mechanics during the operation. 47,48 First, due to more lung tissue was passed during the therapy, the incidence of pneumothorax was significantly higher in central lung cancer than in peripheral lung cancer. Second, patients with chronic obstructive pulmonary disease and emphysema, especially bulla, had an increased incidence of pneumothorax.…”

Section: Discussionmentioning

confidence: 99%

125I Brachytherapy in Locally Advanced Nonsmall Cell Lung Cancer After Progression of Concurrent Radiochemotherapy

Xiang

Liu

et al. 2015

Medicine

View full text Add to dashboard Cite

To investigate the safety and effectiveness of computed tomography (CT)-guided 125I seed implantation for locally advanced nonsmall cell lung cancer (NSCLC) after progression of concurrent radiochemotherapy (CCRT).We reviewed 78 locally advanced NSCLC patients who had each one cycle of first-line CCRT but had progressive disease identified from January 2006 to February 2015 at our institution. A total of 37 patients with 44 lesions received CT-guided percutaneous 125I seed implantation and second-line chemotherapy (group A), while 41 with 41 lesions received second-line chemotherapy (group B).Patients in group A and B received a total of 37 and 41 first cycle of CCRT treatment. The median follow-up was 19 (range 3–36) months. After the second treatment, the total response rate (RR) in tumor response accounted for 63.6% in group A, which was significantly higher than that of group B (41.5%) (P = 0.033). The median progression-free survival time (PFST) was 8.00 ± 1.09 months and 5.00 ± 0.64 months in groups A and B (P = 0.011). The 1-, 2-, and 3-year overall survival (OS) rates for group A were 56.8%, 16.2%, and 2.7%, respectively. For group B, OS rates were 36.6%, 9.8%, and 2.4%, respectively. The median OS time was 14.00 ± 1.82 months and 10.00 ± 1.37 months for groups A and B, respectively (P = 0.059). Similar toxicity reactions were found in both groups. Tumor-related clinical symptoms were significantly reduced and the patients’ quality of life was obviously improved.CT-guided 125I seed implantation proved to be potentially beneficial in treating localized advanced NSCLC; it achieved good local control rates and relieved clinical symptoms without increasing side effects.

show abstract

Section: Discussionmentioning

confidence: 99%

125I Brachytherapy in Locally Advanced Nonsmall Cell Lung Cancer After Progression of Concurrent Radiochemotherapy

Xiang

Liu

et al. 2015

Medicine

View full text Add to dashboard Cite

show abstract

“…A recent large retrospective study [11] of 226 patients, of those 60 patients with carcinoma in situ, treated with high-dose brachytherapy alone showed no difference in local control between patients with in situ carcinomas and those with invasive carcinomas, probably because they were classified as non-invasive on biopsies though infiltrating on bronchoscopy. Furthermore, outcomes were worse for proximally located tumors and in patients treated with one catheter.…”

Section: Discussionmentioning

confidence: 99%

Simultaneous stereotactic body radiation therapy of a primary non-small cell lung cancer and synchronous carcinoma in situ in a medically inoperable patient: case report

Oskan

Kornhuber

Krause³

et al. 2013

Radiat Oncol

View full text Add to dashboard Cite

The co-incidence of synchronous intraepithelial neoplasia and early stage invasive lung cancer is not a rare phenomenon. The need for curative treatment and the invasive potential of squamous cell pulmonary carcinoma in situ have been a topic of controversy. Surgical resection still remains the treatment of choice. Varieties of endoscopic techniques such as brachytherapy were developed as an alternative to surgery in selected patients. External beam radiation therapy has been used traditionally in combination with endobronchial brachytherapy in the treatment of roentgenographically occult lung cancer, and can be offered for all patients, but is handicapped, because these tumors are radiographically invisible. We report the first case of a pulmonary carcinoma in situ that was successfully treated with stereotactic body radiation therapy.

show abstract

“…A recently published retrospective study revealed the efficacy and toxicity of HDR brachytherapy [45]. This study includes 226 patients with endoluminal NSCLC without extrabronchial spread but contraindications for EBRT or surgery.…”

Section: Central Airway Obstructionmentioning

confidence: 99%

Advanced Malignant Lung Disease: What the Specialist Can Offer

Gompelmann

Eberhardt

Herth³

2011

Respiration

View full text Add to dashboard Cite

Lung cancer is not only the most commonly diagnosed cancer worldwide, but it is still the leading cause for cancer-related death. The 5-year survival for lung cancer in Europe and in the USA is totally 16%. Therefore, a palliative therapy regimen is required to control the disease and reduce symptoms with the objective of enhancing quality of life of lung cancer patients. In addition to chemotherapy that is still one of the most important pillars in the treatment of advanced lung cancer, further interventional strategies can be offered to improve a patient’s quality of life. A locoregional tumour progression is frequently associated with malignant pleural effusion or pericardial effusion, central airway obstruction, tracheo-oesophageal fistula, severe haemoptysis or superior vena cava (SVC) syndrome threatening life and necessitating urgent palliation. Recurrent pleural effusion causing dyspnoea can be managed by pleurodesis, serial thoracocentesis or insertion of an indwelling catheter. Symptomatic malignant pericardial effusion often requires an urgent pericardiocentesis. Furthermore, surgical procedures, instillation of sclerosing agents or local chemotherapy should be considered in refractory pericardial effusion. The therapy regimen of central airway stenosis includes mechanical and thermic endoscopic procedures providing rapid relief of symptoms. To prevent recurrence of airway obstruction, the insertion of a stent or palliative brachytherapy provide re-establishment of the patency of obstructed airways. Haemoptysis can be managed by bronchoscopic interventions as well as by arterial embolization or palliative thoracic radiotherapy. The therapy of SVC syndrome is dependent of histology. In small-cell lung cancer, chemotherapy is recommended. In non-small-cell lung cancer, stent insertion and/or radiotherapy are the therapeutic pillars.

show abstract

High-Dose-Rate Brachytherapy for Non–Small-Cell Lung Carcinoma: A Retrospective Study of 226 Patients

Cited by 48 publications

References 33 publications

125I Brachytherapy in Locally Advanced Nonsmall Cell Lung Cancer After Progression of Concurrent Radiochemotherapy

125I Brachytherapy in Locally Advanced Nonsmall Cell Lung Cancer After Progression of Concurrent Radiochemotherapy

Simultaneous stereotactic body radiation therapy of a primary non-small cell lung cancer and synchronous carcinoma in situ in a medically inoperable patient: case report

Advanced Malignant Lung Disease: What the Specialist Can Offer

Contact Info

Product

Resources

About